



Part I


**KDL BIOTECH LIMITED**

Registered Office & Works: Village savroli, Tal. Khalapur, Dist. - Raigad, Maharashtra - 410 202.

**Statement of Standalone Unaudited Results for the Quarter ended as on 30/06/2013**

(Rs. In Lakhs)

Particulars	3 Months ended (30/06/2013)	3 Months ended (31/03/2013)	Corresponding Quarter ended 30/06/2012	Accounting Year ended (31/03/2013) 12 months
	Unaudited	Unaudited	Unaudited	Audited
1. (a) Net Sales/Income from Operations (Net of excise duty)	34.90	161.23	168.41	624.25
(b) Other Operating Income (Job Work Charges Received)	64.08	351.4	315.93	1429.47
<b>Total income from Operations (net)</b>	<b>98.98</b>	<b>512.63</b>	<b>484.34</b>	<b>2053.72</b>
<b>2. Expenses</b>				
a. Cost of Materials consumed	5.39	10.04	4.48	93.91
b. Purchase of stock-in-trade	9.06	112.09	111.44	403.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0	0.00	0.00
d. Employee benefits expenses	120.17	223.34	239.94	879.59
e. Depreciation, Amortisation and Impairment	172.04	171.97	171.96	689.96
f. Other expenses	87.90	195.08	268.96	957.65
<b>Total Expenses</b>	<b>394.56</b>	<b>712.52</b>	<b>796.78</b>	<b>3024.65</b>
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	<b>(295.58)</b>	<b>(199.89)</b>	<b>(312.44)</b>	<b>(970.93)</b>
4. Other Income	6.54	11.77	8.23	33.91
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	<b>(289.04)</b>	<b>(188.12)</b>	<b>(304.21)</b>	<b>(935.02)</b>
6. Finance Costs	171.01	172.43	168.66	685.75
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	<b>(460.05)</b>	<b>(360.55)</b>	<b>(472.87)</b>	<b>(1620.77)</b>
8. Exceptional Items	0.00	0	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax (7+8)	<b>(460.05)</b>	<b>(360.55)</b>	<b>(472.87)</b>	<b>(1620.77)</b>
10. Tax expense		0		
- Current Tax	0.00	0	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0	0.00	0.00
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	<b>(460.05)</b>	<b>(360.55)</b>	<b>(472.87)</b>	<b>(1620.77)</b>
12. Prior Period Item	0.00	0	0.00	0.00
13. Net Profit / (Loss) for the period (11-12)	<b>(460.05)</b>	<b>(360.55)</b>	<b>(472.87)</b>	<b>(1620.77)</b>
14. Share of Profit/ (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	0.00
15. Minority Interest	0		0	0
16. Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associa	<b>(460.05)</b>	<b>(360.55)</b>	<b>(472.87)</b>	<b>(1620.77)</b>
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2403.52	2,403.52	2403.52	2403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accountin	0.00	0.00	0.00	0.00
19.i Earnings Per Share (before extraordinary items) (of Rs. 10 /- each) (not annualised)				
(a) Basic	(1.91)	(1.50)	(1.97)	6.74
(b) Diluted	(1.91)	(1.50)	(1.97)	6.74
19.ii Earnings Per Share (after extraordinary items) (of Rs. 10 /- each) (not annualised)				
(a) Basic	(1.91)	(1.50)	(1.97)	6.74
(b) Diluted	(1.91)	(1.50)	(1.97)	6.74



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad, Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031



Part II Selected Information for the Quarter Ended as on 30/06/2013				
	3 Months ended (30/06/2013)	3 Months ended (31/03/2013)	Corresponding Quarter ended 30/06/2012	Accounting Year ended (31/03/2013) 12 months
<b>A. PARTICULARS OF SHAREHOLDING</b>				
1. Public shareholding				
#NAME?	7485241	7485241	7485241	7485241
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding **				
a) Pledged / Encumbered				
- Number of shares	0	0	0	0
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	0	0	0
- Percentage of shares (as a % of the total share capital of the company)	0	0	0	0
b) Non - Encumbered				
- Number of shares	16549910	16549910	16549910	16549910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%
<b>B. INVESTOR COMPLAINTS</b>				
Pending at the beginning of the quarter	0			
Received during the quarter	0			
Disposed of during the quarter	0			
Remaining unresolved at the end of the quarter	0			

**NOTES**

- 1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.
- 4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is restricted from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- 6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has stayed the matter in view of the reference to BIFR.
- 7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.
- 8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.

**For and on behalf of the Board of Directors**

**Dr. Rajesh Agrawal**  
Director

Place : Mumbai  
Dated : 12.02.2015




**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

## Statement of Standalone Unaudited Results for the Quarter ended as on 30/09/2013

(Rs. In Lakhs)

Particulars	QUARTER ENDED			HALF YEAR ENDED		PREVIOUS ACCOUNTING YEAR ENDED
	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013
	UNAUDITED			UNAUDITED		AUDITED
1. (a) Net Sales/Income from Operations (Net of excise duty)	0.00	34.90	167.14	34.90	335.54	624.25
(b) Other Operating Income (Job Work Charges Received)	0	64.08	490.13	64.08	806.06	1429.47
<b>Total income from Operations (net)</b>	<b>0.00</b>	<b>98.98</b>	<b>657.26</b>	<b>98.98</b>	<b>1141.60</b>	<b>2053.72</b>
<b>2. Expenses</b>						
a. Cost of Materials consumed	0.44	5.39	55.84	5.83	60.33	93.91
b. Purchase of stock-in-trade	0.00	9.06	106.89	9.06	218.34	403.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0	0.00	0.00	0.00
d. Employee benefits expenses	28.67	120.17	262.82	148.83	502.75	879.59
e. Depreciation, Amortisation and Impairment	174.01	172.04	174.18	346.05	346.14	689.96
f. Other expenses	41.64	87.90	272.57	129.53	541.53	957.65
<b>Total Expenses</b>	<b>244.75</b>	<b>394.56</b>	<b>872.30</b>	<b>639.31</b>	<b>1669.09</b>	<b>3024.65</b>
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(244.75)	(295.58)	(215.04)	(540.33)	(527.49)	(970.93)
4. Other Income	6.27	6.54	7.96	12.81	16.20	36.91
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(238.49)	(289.04)	(207.08)	(527.52)	(511.29)	(934.02)
6. Finance Costs	172.88	171.01	172.51	343.89	341.16	685.75
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(411.37)	(460.05)	(379.59)	(871.42)	(852.45)	(1620.77)
8. Exceptional Items	0.00	0.00	0	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax (7+8)	(411.37)	(460.05)	(379.59)	(871.42)	(852.45)	(1620.77)
10. Tax expense			0			
- Current Tax	0.00	0.00	0	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0	0.00	0.00	0.00
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(411.37)	(460.05)	(379.59)	(871.42)	(852.45)	(1620.77)
12. Prior Period Item	0.00	0.00	0	0.00	0.00	0.00
13. Net Profit / (Loss) for the period (11-12)	(411.37)	(460.05)	(379.59)	(871.42)	(852.45)	(1620.77)
14. Share of Profit/ (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00		0.00	0.00	0.00
16. Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	(411.37)	(460.05)	(379.59)	(871.42)	(852.45)	(1620.77)
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
19. i Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)						
(a) Basic	(1.71)	(1.91)	(1.58)	(3.63)	(3.55)	(6.74)
(b) Diluted	(1.71)	(1.91)	(1.58)	(3.63)	(3.55)	(6.74)
19. ii Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)						
(a) Basic	(1.71)	(1.91)	(1.58)	(3.63)	(3.55)	(6.74)
(b) Diluted	(1.71)	(1.91)	(1.58)	(3.63)	(3.55)	(6.74)




KDL BIOTECH LIMITED

Registered Office &amp; Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031




Part II Selected Information for the Quarter Ended as on 30/09/2013						
	QUARTER ENDED			HALF YEAR ENDED		PREVIOUS ACCOUNTING YEAR ENDED
	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013
<b>A. PARTICULARS OF SHAREHOLDING</b>						
1. Public shareholding						
- Number of shares	7485241	7485241	7485241	7485241	7485241	7485241
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding **						
a) Pledged / Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non - Encumbered						
- Number of shares	16549910	16549910	16549910	16549910	16549910	16549910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%	68.86%	68.86%
<b>B. INVESTOR COMPLAINTS</b>						
Pending at the beginning of the quarter	0					
Received during the quarter	0					
Disposed of during the quarter	0					
Remaining unresolved at the end of the quarter	0					

**NOTES**

- 1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.
- 4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is restricted from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- 6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has stayed the matter in view of the reference to BIFR.
- 7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.
- 8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.

For and on behalf of the Board of Directors


Dr. Rajesh Agrawal  
DirectorPlace : Mumbai  
Dated : 12.02.2015**KDL BIOTECH LIMITED**Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO. L17111MH1999PLC000002



(Rs. In Lakhs)

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		PREVIOUS
	31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	YEAR ENDED
	UNAUDITED			UNAUDITED		AUDITED
1. (a) Net Sales/Income from Operations (Net of excise duty)	0.00	0.00	127.47	34.90	463.02	624.25
(b) Other Operating Income (Job Work Charges Received)	0.00	0.00	272.01	64.08	1078.07	1429.47
<b>Total income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>399.48</b>	<b>98.98</b>	<b>1541.09</b>	<b>2053.72</b>
2. Expenses						
a. Cost of Materials consumed	0.00	0.44	23.55	5.83	82.66	93.91
b. Purchase of stock-in-trade	0.00	0.00	111.27	9.06	330.82	403.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	(38.16)	0.00	(38.16)	0.00
d. Employee benefits expenses	22.06	28.67	166.52	170.89	669.27	879.59
e. Depreciation, Amortisation and Impairment	174.01	174.01	171.85	520.06	517.99	689.96
f. Other expenses	21.99	41.64	207.71	151.52	749.24	957.65
<b>Total Expenses</b>	<b>218.06</b>	<b>244.75</b>	<b>642.74</b>	<b>857.37</b>	<b>2311.82</b>	<b>3024.65</b>
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(218.06)	(244.75)	(243.26)	(758.39)	(770.73)	(970.93)
4. Other Income	9.75	6.27	7.95	22.56	24.15	35.91
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(208.31)	(238.49)	(235.31)	(735.83)	(746.58)	(935.02)
6. Finance Costs	172.87	172.88	172.46	516.77	513.63	685.75
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(381.18)	(411.37)	(407.77)	(1252.60)	(1260.21)	(1620.77)
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax (7+8)	(381.18)	(411.37)	(407.77)	(1252.60)	(1260.21)	(1620.77)
10. Tax expense			0.00			
- Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0.00	0.00	0.00	0.00
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(381.18)	(411.37)	(407.77)	(1252.60)	(1260.21)	(1620.77)
12. Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period (11-12)	(381.18)	(411.37)	(407.77)	(1252.60)	(1260.21)	(1620.77)
14. Share of Profit/ (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16. Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	(381.18)	(411.37)	(407.77)	(1252.60)	(1260.21)	(1620.77)
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2403.52	2403.52	2403.52	2403.52	2403.52	2403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting	0.00	0.00	0.00	0.00	0.00	0.00
19.i Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)						
(a) Basic	(1.59)	(1.71)	(1.70)	(5.21)	(5.24)	(6.74)
(b) Diluted	(1.59)	(1.71)	(1.70)	(5.21)	(5.24)	(6.74)
19.ii Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)						
(a) Basic	(1.59)	(1.71)	(1.70)	(5.21)	(5.24)	(6.74)
(b) Diluted	(1.59)	(1.71)	(1.70)	(5.21)	(5.24)	(6.74)




Handwritten signature or initials.


KDL BIOTECH LIMITED

Registered Office &amp; Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO: L24230MH1986PLC040603

Part II Selected Information for the Quarter Ended as on 31/12/2013						
PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		PREVIOUS YEAR ENDED
	31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
	UNAUDITED			UNAUDITED		AUDITED
<b>A. PARTICULARS OF SHAREHOLDING</b>						
1. Public shareholding						
- Number of shares	7485241	7485241	7485241	7485241	7485241	7485241
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding **						
a) Pledged / Encumbered						
- Number of shares	0	0	0	0	0	0
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	0	0	0	0	0
- Percentage of shares (as a % of the total share capital of the company)	0	0	0	0	0	0
b) Non - Encumbered						
- Number of shares	16549910	16549910	16549910	16549910	16549910	16549910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%	68.86%	68.86%
<b>B. INVESTOR COMPLAINTS</b>						
Pending at the beginning of the quarter	1					
Received during the quarter	0					
Disposed of during the quarter	0					
Remaining unresolved at the end of the quarter	1					
<p>1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.</p> <p>2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.</p> <p>3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.</p> <p>4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.</p> <p>5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is restricted from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.</p> <p>6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has stayed the matter in view of the reference to BIFR.</p> <p>7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.</p> <p>8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.</p>						
<p style="text-align: right;">For and on behalf of the Board of Directors</p> <p style="text-align: right;"> Dr. Rajesh Agrawal Director</p>						
<p>Place : Mumbai Dated : 12.02.2015</p>						


**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO: L21300GJ1999PL1000006

**Statement of Standalone Unaudited Results for the Quarter ended as on 31/03/2014**

(Rs. in Lakhs)

Particulars	QUARTER ENDED			YEAR ENDED	PREVIOUS YEAR ENDED
	31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
	UNAUDITED			UNAUDITED	AUDITED
1 (a) Net Sales/Income from Operations (Net of excise duty)	0.00	0.00	161.23	34.90	624.25
(b) Other Operating Income (Job Work Charges Received)	0.00	0.00	351.40	64.08	1,429.47
<b>Total income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>512.63</b>	<b>98.98</b>	<b>2,053.72</b>
<b>2. Expenses</b>					
a. Cost of Materials consumed	0.00	0.00	10.04	5.83	98.91
b. Purchase of stock-in-trade	0.00	0.00	112.09	9.06	432.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
d. Employee benefits expenses	99.56	22.06	223.34	270.45	879.59
e. Depreciation, Amortisation and Impairment	170.23	174.01	171.97	690.29	639.96
f. Other expenses	17.60	21.99	195.08	169.12	957.34
<b>Total Expenses</b>	<b>287.39</b>	<b>218.06</b>	<b>712.52</b>	<b>1,144.76</b>	<b>3,024.34</b>
<b>3. Profit/(Loss) from Operations before other income, finance costs and exceptional items (1-2)</b>	<b>(287.39)</b>	<b>(218.06)</b>	<b>(199.89)</b>	<b>(1,045.78)</b>	<b>(970.62)</b>
<b>4. Other Income</b>	<b>13.22</b>	<b>9.75</b>	<b>11.77</b>	<b>35.78</b>	<b>35.91</b>
<b>5. Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>(274.16)</b>	<b>(208.31)</b>	<b>(188.12)</b>	<b>(1,009.99)</b>	<b>(934.71)</b>
<b>6. Finance Costs</b>	<b>169.11</b>	<b>172.87</b>	<b>172.43</b>	<b>685.88</b>	<b>686.06</b>
<b>7. Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5+6)</b>	<b>(443.27)</b>	<b>(381.18)</b>	<b>(360.55)</b>	<b>(1,695.87)</b>	<b>(1,620.77)</b>
<b>8. Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9. Profit/(Loss) from ordinary activities before tax (7+8)</b>	<b>(443.27)</b>	<b>(381.18)</b>	<b>(360.55)</b>	<b>(1,695.87)</b>	<b>(1,620.77)</b>
<b>10. Tax expense</b>					
- Current Tax	0.00	0.00	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0.00	0.00	0.00
<b>11. Net Profit/(Loss) from ordinary activities after tax (9-10)</b>	<b>(443.27)</b>	<b>(381.18)</b>	<b>(360.55)</b>	<b>(1,695.87)</b>	<b>(1,620.77)</b>
<b>12. Prior Period Item</b>					
<b>13. Net Profit/(Loss) for the period (11-12)</b>	<b>(443.27)</b>	<b>(381.18)</b>	<b>(360.55)</b>	<b>(1,695.87)</b>	<b>(1,620.77)</b>
<b>14. Share of Profit/(Loss) of associates (Face Value of the Share shall be indicated)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>15. Minority Interest</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>16. Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)</b>	<b>(443.27)</b>	<b>(381.18)</b>	<b>(360.55)</b>	<b>(1,695.87)</b>	<b>(1,620.77)</b>
<b>17. Paid-up equity share capital, Equity shares of Rs. 10 each</b>	<b>2,403.52</b>	<b>2,403.52</b>	<b>2,403.52</b>	<b>2,403.52</b>	<b>2,403.52</b>
<b>18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>19.i Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)</b>					
(a) Basic	(1.84)	(1.59)	(1.50)	(7.06)	(5.74)
(b) Diluted	(1.84)	(1.59)	(1.50)	(7.06)	(5.74)
<b>19.ii Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)</b>					
(a) Basic	(1.84)	(1.59)	(1.50)	(7.06)	(6.74)
(b) Diluted	(1.84)	(1.59)	(1.50)	(7.06)	(6.74)



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroll, Tal. : Khalapur, Dist. Raigad., Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO: L24230MH1986PLC040603

CIN NO: L24230MH1986PLC040603



Part II					
Selected Information for the Quarter Ended as on 31/03/2014					
A. PARTICULARS OF SHAREHOLDING	QUARTER ENDED			YEAR ENDED	PREVIOUS YEAR ENDED
	31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
1. Public shareholding					
- Number of shares	7485241	7485241	7485241	7485241	7485241
- Percentage of shareholding	31.14%	31.14%	31.14%	0.3114	31.14%
2. Promoters and Promoter Group Shareholding **					
a) Pledged / Encumbered					
- Number of shares	0	0	0	0	0
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	0	0	0	0
- Percentage of shares (as a % of the total share capital of the company)	0	0	0	0	0
b) Non - Encumbered					
- Number of shares	16549910	16549910	16549910	16549910	16549910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	1	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	0.6886	0.6886	68.86%
B. INVESTOR COMPLAINTS					
Pending at the beginning of the quarter	0				
Received during the quarter	0				
Disposed of during the quarter	0				
Remaining unresolved at the end of the quarter	0				


**NOTES**

- 1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.
- 4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is registered from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- 6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has stayed the matter in view of the reference to BIFR.
- 7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.
- 8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.

For and on behalf of the Board of Directors

Dr. Rajesh Agrawal  
Director

Place : Mumbai  
Dated : 12.02.2015



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031





Part I


KDL BIOTECH LIMITED

Registered Office & Works: Village savroli, Tal. Khalapur, Dist. - Raigad, Maharashtra - 410 202.

Statement of Standalone Unaudited Results for the Quarter ended as on 30/06/2014

(Rs. In Lakhs)

Particulars	3 Months ended (30/06/2014)	3 Months ended (31/03/2014)	Corresponding 3 months ended in the previous year (30/06/2013)	Previous Year ended (31/03/2014) 12 months	Previous Year ended (31/03/2013) 12 months
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. (a) Net Sales/Income from Operations (Net of excise duty)	0.00	0.00	34.90	34.90	624.25
(b) Other Operating Income (Job Work Charges Received)	0.00	0.00	64.08	64.08	1429.47
<b>Total income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>98.98</b>	<b>98.98</b>	<b>2053.72</b>
<b>2. Expenses</b>					
a. Cost of Materials consumed	0.00	0.00	5.39	5.83	93.91
b. Purchase of stock-in-trade	0.00	0.00	9.06	9.06	403.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
d. Employee benefits expenses	11.79	99.56	120.17	270.45	879.59
e. Depreciation, Amortisation and Impairment	171.90	170.23	172.04	690.29	689.96
f. Other expenses	19.09	17.60	87.90	169.12	957.65
<b>Total Expenses</b>	<b>202.77</b>	<b>287.39</b>	<b>394.56</b>	<b>1144.76</b>	<b>3024.65</b>
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(202.77)	(287.39)	(295.58)	(1045.78)	(970.93)
4. Other Income	3.64	13.22	6.54	35.78	35.91
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(199.13)	(274.16)	(289.04)	(1009.99)	(935.02)
6. Finance Costs	121.77	169.11	171.01	685.88	685.75
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(320.90)	(443.27)	(460.05)	(1695.87)	(1620.77)
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax (7+8)	(320.90)	(443.27)	(460.05)	(1695.87)	(1620.77)
10. Tax expense					
- Current Tax	0.00	0.00	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0.00	0.00	0.00
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(320.90)	(443.27)	(460.05)	(1695.87)	(1620.77)
12. Prior Period Item	0.00	-	0.00	0.00	0.00
13. Net Profit / (Loss) for the period (11-12)	(320.90)	(443.27)	(460.05)	(1695.87)	(1620.77)
14. Share of Profit/ (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0	0.00	0.00
<b>16. Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)</b>	<b>(320.90)</b>	<b>(443.27)</b>	<b>(460.05)</b>	<b>(1,695.87)</b>	<b>(1620.77)</b>
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2,403.52	2,403.52	2403.52	2403.52	2,403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00
19.i Earnings Per Share (before extraordinary items) (of Rs. 10 /- each) (not annualised)					
(a) Basic	(1.34)	(1.84)	(1.91)	(7.06)	(6.74)
(b) Diluted	(1.34)	(1.84)	(1.91)	(7.06)	(6.74)
19.ii Earnings Per Share (after extraordinary items) (of Rs. 10 /- each) (not annualised)					
(a) Basic	(1.34)	(1.84)	(1.91)	(7.06)	(6.74)
(b) Diluted	(1.34)	(1.84)	(1.91)	(7.06)	(6.74)



*[Handwritten signature]*

KDL BIOTECH LIMITED

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO: L24230MH1986PLC040603



Part II Selected Information for the Quarter Ended as on 30/06/2014					
	3 Months ended (30/06/2014)	3 Months ended (31/03/2014)	Corresponding 3 months ended in the previous year (30/06/2013)	Previous Year ended (31/03/2014) 12 months	Previous Year ended (31/03/2013) 12 months
<b>A. PARTICULARS OF SHAREHOLDING</b>					
1. Public shareholding					
- Number of shares	7485241	7485241	7485241	7485241	7485241
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding **					
a) Pledged / Encumbered					
- Number of shares	0	0	0	0	0
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	0	0	0	0
- Percentage of shares (as a % of the total share capital of the company)	0	0	0	0	0
b) Non - Encumbered					
- Number of shares	16549910	16549910	16549910	16549910	16549910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%	68.86%
<b>B. INVESTOR COMPLAINTS</b>					
Pending at the beginning of the quarter	0				
Received during the quarter	0				
Disposed of during the quarter	0				
Remaining unresolved at the end of the quarter	0				


**NOTES**

- 1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.
- 4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is registered from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- 6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has started proceedings.
- 7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.
- 8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.
- 9) The Company has declared as "Sick Industrial Company" by BIFR by order dated 16/05/2014 under SICA, 1998.

For and on behalf of the Board of Directors

Dr. Rajesh Agrawal  
Director

Place : Mumbai  
Dated : 12.02.2015



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031


CIN NO. L27201MH1998PL100000



## Statement of Standalone Unaudited Results for the Quarter ended as on 30/09/2014

(Rs. In Lakhs)


Particulars	QUARTER ENDED			HALF YEAR ENDED		Previous Year ended (31/03/2014) 12 months (Unaudited)	Previous Year ended (31/03/2013) 12 months (Audited)
	30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013		
	UNAUDITED			UNAUDITED			
1. (a) Net Sales/Income from Operations (Net of excise duty)	0.00	0.00	0.00	0.00	34.90	34.90	624.25
(b) Other Operating Income (Job Work Charges Received)	0.00	0.00	0.00	0.00	64.08	64.08	1429.47
<b>Total income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>98.98</b>	<b>98.98</b>	<b>2053.72</b>
<b>2. Expenses</b>							
a. Cost of Materials consumed	0.00	0.00	0.44	0.00	5.83	5.83	98.91
b. Purchase of stock-in-trade	0.00	0.00	0.00	0.00	9.06	9.06	408.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00
d. Employee benefits expenses	6.49	11.79	28.67	18.28	148.83	270.45	879.59
e. Depreciation, Amortisation and Impairment	173.78	171.90	174.01	345.68	346.05	690.29	609.96
f. Other expenses	23.54	19.09	41.64	42.63	129.53	169.12	937.65
<b>Total Expenses</b>	<b>203.82</b>	<b>202.77</b>	<b>244.75</b>	<b>406.59</b>	<b>639.31</b>	<b>1144.76</b>	<b>3024.65</b>
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(203.82)	(202.77)	(244.75)	(406.59)	(540.33)	(1045.78)	(970.93)
4. Other Income	3.73	3.64	6.27	7.37	12.81	35.78	35.91
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(200.09)	(199.13)	(238.49)	(399.22)	(527.52)	(1009.99)	(935.02)
6. Finance Costs	123.10	121.77	172.88	244.87	343.89	685.88	645.75
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(323.19)	(320.90)	(411.37)	(644.08)	(871.42)	(1695.87)	(1620.77)
8. Exceptional Items	0.00	0.00	0.00	-	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax (7+8)	(323.19)	(320.90)	(411.37)	(644.08)	(871.42)	(1695.87)	(1620.77)
10. Tax expense							
- Current Tax	0.00	0.00	0.00	-	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0.00	-	0.00	0.00	0.00
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(323.19)	(320.90)	(411.37)	(644.08)	(871.42)	(1695.87)	(1620.77)
12. Prior Period Item	0.00	0.00	0.00	-	0.00	0.00	0.00
13. Net Profit / (Loss) for the period (11-12)	(323.19)	(320.90)	(411.37)	(644.08)	(871.42)	(1695.87)	(1620.77)
14. Share of Profit/ (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	-	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0.00	-	0.00	0.00	0.00
16. Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	(323.19)	(320.90)	(411.37)	(644.08)	(871.42)	(1,695.87)	(1620.77)
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2,403.52	2,403.52	2,403.52		2,403.52	2403.52	2,403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00		0.00	0.00	0.00
19.i Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)							
(a) Basic	(1.34)	(1.34)	(1.71)	(2.68)	(3.63)	(7.06)	(6.74)
(b) Diluted	(1.34)	(1.34)	(1.71)	(2.68)	(3.63)	(7.06)	(6.74)
19.ii Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)							
(a) Basic	(1.34)	(1.34)	(1.71)	(2.68)	(3.63)	(7.06)	(6.74)
(b) Diluted	(1.34)	(1.34)	(1.71)	(2.68)	(3.63)	(7.06)	(6.74)



KDL BIOTECH LIMITED CIN NO: L24230MH2007PLC010002

Registered Office &amp; Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

Part II		Selected Information for the Quarter Ended as on 30/09/2014						
		UNAUDITED			UNAUDITED		Current Year ended (31/03/2014) 12 months (Unaudited)	Previous Year ended (31/03/2013) 12 months (Audited)
A. PARTICULARS OF SHAREHOLDING		30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013		
1. Public shareholding								
- Number of shares		7485241	7485241	7485241	7485241	7485241	7485241	7485241
- Percentage of shareholding		31.14%	31.14%	31.14%	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding **								
a) Pledged / Encumbered								
- Number of shares		0	0	0	0	0	0	0
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)		0	0	0	0	0	0	0
- Percentage of shares (as a % of the total share capital of the company)		0	0	0	0	0	0	0
b) Non - Encumbered								
- Number of shares		16549910	16549910	16549910	16549910	16549910	16549910	16549910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)		100%	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)		68.86%	68.86%	68.86%	68.86%	68.86%	68.86%	68.86%
B. INVESTOR COMPLAINTS								
Pending at the beginning of the quarter		0						
Received during the quarter		1						
Disposed of during the quarter		0						
Remaining unresolved at the end of the quarter		1						

#### NOTES

- 1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.
- 4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is registered from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- 6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT has stayed the matter in view of the reference to BIFR.
- 7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.
- 8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.
- 9) The Company has declared as "Sick Industrial Company" by BIFR by order dated 16/05/2014 under SICA, 1998.
- 10) The State Bank of India has taken symbolic possession of the Factory of KDL Biotech Ltd. was already taken over by the Banker on 9th July, 2014.
- 11) The Company is existing but in reality no operation is carried on and Company only bear the fixed
- 12) The Company is required to revive otherwise the Company can not settle its dues with the Bankers and
- 13) Revival Scheme has already been submitted to BIFR and Canara Bank was appointed as Operating
- 14) There was huge Income Tax Accumulated Losses in the Company.

For and on behalf of the Board of Directors

  
Dr. Rajesh Agrawal  
Director

Place : Mumbai  
Dated : 12.02.2015



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khaiapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO: L21920MH2005PLC000003

## Statement of Standalone Unaudited Results for the Quarter ended as on 31/12/2014

(Rs. In Lakhs)

Particulars	Quarter ended			Nine Months ended		Previous Year ended (31/03/2014) 12 months (Unaudited)	Previous Year ended (31/03/2013) 12 months (Audited)
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013		
	Unaudited			Unaudited			
1. (a) Net Sales/Income from Operations (Net of excise duty)	0.00	0.00	0.00	0.00	34.90	34.90	624.25
(b) Other Operating Income (Job Work Charges Received)	0.00	0.00	0	0.00	64.08	64.08	1429.47
<b>Total income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>98.98</b>	<b>98.98</b>	<b>2053.72</b>
<b>2. Expenses</b>							
a. Cost of Materials consumed	0.00	0.00	0.00	0.00	5.83	5.83	93.91
b. Purchase of stock-in-trade	0.00	0.00	0.00	0.00	9.06	9.06	403.54
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00
d. Employee benefits expenses	5.07	6.49	22.06	23.35	170.89	270.45	879.59
e. Depreciation, Amortisation and impairment	173.54	173.78	174.01	519.22	520.06	690.29	889.96
f. Other expenses	28.60	23.54	21.99	71.23	151.52	169.12	857.65
<b>Total Expenses</b>	<b>207.22</b>	<b>203.82</b>	<b>218.06</b>	<b>613.81</b>	<b>857.37</b>	<b>1144.76</b>	<b>3024.65</b>
3. Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(207.22)	(203.82)	(218.06)	(613.81)	(758.39)	(1045.78)	(970.93)
4. Other Income	1.66	3.73	9.75	9.04	22.56	35.78	35.91
5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(205.56)	(200.09)	(208.31)	(604.77)	(735.83)	(1009.99)	(935.02)
6. Finance Costs	127.17	123.10	172.87	372.04	516.77	685.88	685.75
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(332.73)	(323.19)	(381.18)	(976.81)	(1252.60)	(1695.87)	(1620.77)
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax (7+8)	(332.73)	(323.19)	(381.18)	(976.81)	(1252.60)	(1695.87)	(1620.77)
10. Tax expense							
- Current Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
- Deferred Tax Assets Written Off	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(332.73)	(323.19)	(381.18)	(976.81)	(1252.60)	(1695.87)	(1620.77)
12. Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period (11-12)	(332.73)	(323.19)	(381.18)	(976.81)	(1252.60)	(1695.87)	(1620.77)
14. Share of Profit / (Loss) of associates (Face Value of the Share shall be indicated)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	(332.73)	(323.19)	(381.18)	(976.81)	(1252.60)	(1695.87)	(1620.77)
17. Paid-up equity share capital, Equity shares of Rs. 10 each	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00	0.00
19.i Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)							
(a) Basic	(1.38)	(1.34)	(1.59)	(4.06)	(5.21)	(7.06)	(6.74)
(b) Diluted	(1.38)	(1.34)	(1.59)	(4.06)	(5.21)	(7.06)	(6.74)
19.ii Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)							
(a) Basic	(1.38)	(1.34)	(1.59)	(4.06)	(5.21)	(7.06)	(6.74)
(b) Diluted	(1.38)	(1.34)	(1.59)	(4.06)	(5.21)	(7.06)	(6.74)



KDL BIOTECH LIMITED CIN NO: 2723012014000000

Registered Office &amp; Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202

Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031



Part II		Selected Information for the Quarter Ended as on 31/12/2014					Biotech	
Particulars	Quarter ended			Nine Months ended		Previous Year ended (31/03/2014)	Previous Year ended (31/03/2013)	
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	12 months (Unaudited)	12 months (Audited)	
<b>A. PARTICULARS OF SHAREHOLDING</b>								
1 Public shareholding								
- Number of shares	7485241	7485241	7485241	7485241	7485241	7485241	7485241	
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%	31.14%	31.14%	31.14%	
2. Promoters and Promoter Group Shareholding **								
a) Pledged / Encumbered								
- Number of shares	0	-	-	-	-	-	-	
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0	-	-	-	-	-	-	
- Percentage of shares (as a % of the total share capital of the company)	0	-	-	-	-	-	-	
b) Non - Encumbered								
- Number of shares	16549910	16549910	16549910	16549910	16549910	16549910	16549910	
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%	100%	100%	100%	
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%	68.86%	68.86%	68.86%	
<b>B. INVESTOR COMPLAINTS</b>								
Pending at the beginning of the quarter	0							
Received during the quarter	1							
Disposed of during the quarter	0							
Remaining unresolved at the end of the quarter	1							

**NOTES**


- 1) Previous period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
- 2) The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
- 3) The Company had submitted revised One Time Settlement (OTS) proposal to the bankers which is pending for consent.
- 4) State Bank of India, on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFAESI) Act, 2002 to the Company and the company has replied to the said notice.
- 5) The Company has filed reference with BIFR on 29-11-2012 based on Balance Sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is registered from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- 6) The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues. Based on the reference made to the BIFR by the Company, DRT
- 7) The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks, the amount of which is unascertained. The Company's management believes that pending finality of the reference filed with BIFR, no penal interest and additional interest needs to be accrued on the loans at this point of time.
- 8) The workers of the Company are on strike since April 29, 2013. Due to this all the production activities are stand still.
- 9) The Company has declared as "Sick Industrial Company by BIFR by order dated 16/05/2014 under SICA, 1998.
- 10) The State Bank of India has taken symbolic possession of the Factory of KDL Biotech Ltd. was already taken over by the Banker on 9th July, 2014.
- 11) The Company is existing but in reality no operation is carried on and Company only bear the fixed expenses.
- 12) The Company is required to revive otherwise the Company can not settle its dues with the Bankers and
- 13) Revival Scheme has already been submitted to BIFR and Canara Bank was appointed as Operating
- 14) There was huge Income Tax Accumulated Losses in the Company.

For and on behalf of the Board of Directors

*[Signature]*

Dr. Rajesh Agrawal  
Director

Place : Mumbai  
Dated : 12.02.2015



**KDL BIOTECH LIMITED**

Registered Office & Works : Village Savroli, Tal. : Khalapur, Dist. Raigad., Pin - 410 202  
Tel. : (02192) 274 026 To 274 029 • Fax : (02192) 274 031

CIN NO. 272202/KOL/2007/0001